Retina Synthesis

In this episode, we discuss the 3 year results of the Phase 2 trial of the Adverum intravitreal gene therapy with Dr. Dilsher Dhoot, California Retina Consultants, Adjunct Clinical Professor Ophthalmology, Keck School of Medicine of USC.

In this episode we discuss the impressive Phase 4 results of the Belvedere Trial for treatment of neovascular AMD with Dr. Michael Klufas of Wills Eye Hospital.

In our latest episode with the discuss the promising results of a Phase I clinical trial looking at kamuvudine 8 an inflammasome inhibitor in the treatment of geographic atrophy with Dr. Jayakrishna Ambati, Guerry Professor of Ophthalmology at the University of Virginia School of Medicine.

In this episode, we discuss real world treatment of proliferative diabetic retinopathy using data from the Vestrum data base; with Dr. Adrienne Scott, Fred M. Leader Family Retina Professor of the Wilmer Eye Institute and Johns Hopkins University School of Medicine.

In this episode, we discuss the pathbreaking use of an encapsulated cell therapy that produces CNTF for the successful treatment of MacTel with Roger Goldberg, MD, from Walnut Creek, CA.

In our latest update, we discuss strategies for developing a teleretinology network with Dr. Glenn Yiu, Professor of Ophthalmology, University of California, Davis.

In our latest update we discuss the prevention and treatment of endophthalmitis with one of the world's leading authorities, Dr. Harry Flynn , holder of the J. Donald M. Gass Distinguished Chair In Ophthalmology at the Bascom Palmer Eye Institute.

We discuss early studies of ophthalmic artery angioplasty in cases of advanced geographic atrophy with Dr. Philip Rosenfeld of the Bascom Palmer Eye Institute.

In our latest episode, we discuss the results of the PRIMA retinal implant in treating eyes with center involved geographic atrophy as presented in a recent New England Journal of Medicine article. 85% of eyes had meaningful improvement in vision at one year with Dr. Daniel Palanker, Professor of Ophthalmology and Electrical Engineering, Stanford University.

In this episode, In our latest episode,  we discuss the results of a randomized trial comparing the Iluvien sustained release steroid implant to aflibercept in the treatment of diabetic macular edema with Dr. Michael Singer, Clinical Professor, University of Texas Health Sciences Center, San Antonio.

We discuss the diagnosis and management of central serous chorioretinopathy with photodynamic therapy with Dr. Andrew Lotery, Professor of Ophthalmology, University of Southhampton, United Kingdom.

In this episode, we discuss the use of low dose cryogenic application for anesthesia prior to intravitreal injection with Dr. Michael Singer, Adjunct Professor University of Texas Health Science Center, San Antonio.

In our latest update, we discuss current treatment of retinopathy of prematurity as well as new developments in disease prevention with Dr. Darius Moshfeghi, Professor of Ophthalmology, Stanford University, Director, Retina Division, Byers Eye Institute.

In this update, we review the TKI program of Eyepoint Pharmaceuticals with Dr. Jay Duker, President and CEO.

We discuss a study that showed that an artificial intelligence powered system can detect clinically significant fluid as well as experienced observers using the Notal Home OCT with Dr. Ted Leng, Professor of Ophthalmology, Byers Eye Institute, Stanford University.

We discuss studies documenting the undertreatment of diabetic macular edema and possible strategies for alleviating it with Dr. Matthew Starr, Assistant Professor, Mayo Clinic, Rochester, Minnesota.

In this episode, we discuss promising results of gene therapy, administered suprachoroidally, for the treatment of nonproliferation diabetic retinopathy without macular edema with Charles Wykoff, MD, Ph. D., Retina Consultants of Houston.

We discuss promising Phase 2 results from Nanoscope regarding the use of optogenetics for treatment of retinal degenerations with Allen Ho, MD, Professor of Ophthalmology, Wills Eye Hospital.

We discuss the early results of the use of artificial intelligence in the management of macular disorders with Dr. Pearse Keane, the world's first Professor of Artificial Medical Intelligence, University College London, Moorfields Eye Hospital.

We discuss with Dr. Rajesh C. Rao, Leonard Miller Professor of Ophthalmology, Kellogg Eye Center, University of Michigan, the results of a Phase I trial exploring the use of stem cells injected subretinally in eyes with geographic atrophy. The results are promising.

We discuss  the early results of gene therapy of neovascular AMD by intravitreal administration of the vector with Dr. Glenn Yiu, Professor of Ophthalmology, University of California, Davis.

We discuss the long term results of the Truckee Study, a stage 4 clinical trial in the treatment of neovascular AMD with faricimab with Dr. Arshad Khanani from Sierra Eye Associates, Reno, Nevada.

We discuss the use of a tyrosinase kinase inhibitor, EY-1901, for the treatment of diabetic macular edema with Dr. Yasha Modi, New York University, and Manhattan Eye Ear and Throat Hospital, New York.

We discuss early results from the study of photobiomodulation for the treatment of dry AMD with Dr. David Boyer, Adjunct Professor of Clinical Ophthalmology,  Keck School of Medicine of USC, Roski Eye Institute.

We review long term results from the PHOTON Study with Eric Schneider, MD, Tennessee Retina, Nashville, TM.